TITLE

Vimentin as a poor prognostic factor for triple-negative breast cancer

AUTHOR(S)
Yamashita, Nami; Tokunaga, Eriko; Kitao, Hiroyuki; Hisamatsu, Yuichi; Taketani, Kenji; Akiyoshi, Sayuri; Okada, Satoko; Aishima, Shinichi; Morita, Masaru; Maehara, Yoshihiko
PUB. DATE
May 2013
SOURCE
Journal of Cancer Research & Clinical Oncology;May2013, Vol. 139 Issue 5, p739
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, is a highly heterogeneous disease. Recent studies suggest that there are links between TNBC and the epithelial-mesenchymal transition (EMT). To identify prognostic biomarkers and novel therapeutic targets, vimentin, one of the most major factors associated with EMT was investigated in TNBC. Materials and methods: Sporadic invasive ductal carcinoma specimens were obtained from 659 Japanese patients, and 90 (14 %) cases were diagnosed as TNBC. The vimentin mRNA and protein expression levels were evaluated by quantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. Results: The mRNA expression of vimentin was significantly upregulated in the basal-type breast cancer cell line. Immunohistochemically, the vimentin expression was significantly higher ( p = 0.0042) in TNBC compared with the other subtypes. Vimentin expression was associated with a younger age ( p = 0.016), high nuclear grade ( p = 0.023) and high Ki67 expression ( p < 0.0001), and a poorer prognosis in terms of both the recurrence-free survival (RFS) ( p = 0.0058) and overall survival (OS) ( p = 0.013) in TNBC patients. A multivariate analysis showed that vimentin expression was an independent prognostic factor for the RFS ( p = 0.043). Vimentin expression was also associated with a significantly shorter RFS ( p = 0.021) and OS ( p = 0.017) in patients with basal-like breast cancer (BLBC). Conclusions: The elevated expression of vimentin contributes to the aggressive phenotype and poor prognosis in TNBC. Vimentin expression might be useful as a biomarker for the prognosis of TNBC.
ACCESSION #
86977493

 

Related Articles

  • Clinicopathological study of centrally necrotizing carcinoma of the breast. Yanling Zhang; Yurong Ou; Donghong Yu; Xiang Yong; Xiaoli Wang; Bo Zhu; Qiong Zhang; Lei Zhou; Zhaogen Cai; Zenong Cheng // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: Centrally necrotizing carcinoma of the breast (CNC) represents a newly-identified subset of breast cancer. The clinical and pathological characteristics of this breast cancer subtype are not yet completely understood. Methods: We assessed the clinicopathological characteristics of 73...

  • Morphological profile and receptor status in breast carcinoma: An institutional study. Rao, Chandrika; Shetty, Jayaprakash; HL, Kishan Prasad // Journal of Cancer Research & Therapeutics;Jan-Mar2013, Vol. 9 Issue 1, p44 

    Context: The data on histological and receptor status in breast cancer in an Indian population is limited as receptor status is not routinely carried out for these patients. In the present study, receptor status was analyzed and it was correlated with morphological prognostic parameters....

  • Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country. Subramaniam, S.; Bhoo-Pathy, N.; Taib, N.; Tan, G.; See, M.; Jamaris, S.; Ho, G.; Looi, L.; Yip, C. // World Journal of Surgery;Oct2015, Vol. 39 Issue 10, p2450 

    Introduction: Breast cancer can be divided into four subtypes based on the expressions of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor-2 (HER2). Each subtype has different clinicopathological features and outcomes. Objective: To compare the...

  • Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? Buggi, F.; Folli, S.; Curcio, A.; Casadei-Giunchi, D.; Rocca, A.; Pietri, E.; Medri, L.; Serra, L. // Annals of Oncology;Aug2012, Vol. 23 Issue 8, p2042 

    Background Invasive multiple breast cancers with a single histological feature (MBCSH) are routinely assessed for biological parameters to indicate adjuvant treatments only in the largest invasive carcinomas. However, the heterogeneity of individual foci in multiple carcinomas has not been...

  • Application of tissue microarrays for receptor immunohistochemistry in breast carcinoma. Glajcar, Anna; Kaczmarczyk, Karolina; Szpor, Joanna; Okon, Krzysztof // Folia Histochemica et Cytobiologica;2013, Vol. 51 Issue 4, p326 

    The current treatment of breast cancer, the most frequent malignancy found in females, requires the study of biomarkers. The standard set of these includes at least an estrogen receptor, a progesterone receptor and a HER2 receptor, although many other factors have been shown to contribute to the...

  • Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities. Munoz, J.; Wheler, J.; Kurzrock, R. // Cancer & Metastasis Reviews;Dec2015, Vol. 34 Issue 4, p547 

    Estrogen and progesterone receptors (ERs and PRs) are known for their prognostic as well as treatment predictive value in breast cancer. Although these receptors are differentially expressed in some other malignancies, and likely participate in the biology of those cancer types, the relevance to...

  • Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer. Sae Byul Lee; Jong Won Lee; Jong Han Yu; Beom Seok Ko; Hee Jeong Kim; Byung Ho Son; Gyungyub Gong; Hee Jin Lee; Sung-Bae Kim; Kyung Hae Jung; Jin-Hee Ahn; Woochang Lee; Joohon Sung; Sei-Hyun Ahn // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background Despite the preclinical outcomes and biologic significance of the presence of the human epidermal growth factor receptor-2 (HER2) extracellular domain (ECD), there is little evidence supporting the measurement of ECD levels in any clinical setting. The aim of this study was to...

  • Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review. Kandula, Mahesh; Kumar Ch, Kalyan; Raju YS, Ammi // World Journal of Oncology;2013, Vol. 4 Issue 3, p137 

    Tripple negative breast cancer (TNBC) accounts for approximately 15% of breast cancers. It is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER-2 Over expression. Expression of ER, PR and HER-2 plays an important role in therapeutic assessment of patients with...

  • PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis. Paul, A; Gunewardena, S; Stecklein, S R; Saha, B; Parelkar, N; Danley, M; Rajendran, G; Home, P; Ray, S; Jokar, I; Vielhauer, G A; Jensen, R A; Tawfik, O; Paul, S // Cell Death & Differentiation;Sep2014, Vol. 21 Issue 9, p1469 

    Triple-negative breast cancer (TNBC) is a distinct breast cancer subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2/neu), and the patients with TNBC are often diagnosed with higher rates of recurrence and metastasis....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics